Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05307731 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fingolimod for Type 2 Diabetes Mellitus

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Mar 15, 2026 → Mar 15, 2028
See other at-risk trials from General Hospital of Shenyang Military Region

Record History

  1. Primary and study completion pushed from Mar 15, 2026 to Mar 15, 2028v5
  2. Primary and study completion dates: Mar 15, 2025 to Mar 15, 2026v4
  3. Primary and study completion dates: Mar 15, 2024 to Mar 15, 2025v3
  4. Primary and study completion dates: Mar 15, 2023 to Mar 15, 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .
Trial Details
NCT Number NCT05307731
Lead Sponsor General Hospital of Shenyang Military Region
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov